A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), small molecules, such as ibrutinib, are beginning to play a significant role, particularly in patients with multiply relapsed or chemotherapy-refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucker, David L, Rule, Simon A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484687/
https://www.ncbi.nlm.nih.gov/pubmed/26150724
http://dx.doi.org/10.2147/TCRM.S73559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484687/
https://www.ncbi.nlm.nih.gov/pubmed/26150724
http://dx.doi.org/10.2147/TCRM.S73559

Ejemplares similares